rs10895816 — GRIA4

GRIA4 and the Glutamate Receptor Architecture of Restless Legs Syndrome

Most people picture restless legs syndrome (RLS) as a problem of dopamine — the neurotransmitter that governs movement and reward. The clinical reality is more complex. In RLS, the brain's excitatory wiring is equally implicated: glutamate, the primary fast-excitatory neurotransmitter, appears to be chronically elevated in the thalamus at exactly the time it should quiet down for sleep. GRIA4 encodes the GluA4 subunit of the AMPA receptor¹¹ GRIA4 encodes the GluA4 subunit of the AMPA receptor
AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors are the main fast-excitatory receptors in the brain, assembled from four GluA subunit types (GluA1-4) encoded by GRIA1-4, a principal component of the brain's fast excitatory machinery. A common variant within or near GRIA4 — rs10895816 — is now one of the strongest genetic signals yet discovered for RLS, implying that glutamatergic overactivity, partly encoded in AMPA receptor genetics, is a genuine biological driver of this condition.

The Mechanism

rs10895816 sits at chromosomal position 105,414,395 on chromosome 11 (GRCh38), within an intronic region near GRIA4. It does not alter the GRIA4 protein sequence, but intronic and regulatory variants at GWAS significance typically act by modulating gene expression levels, splicing efficiency, or enhancer activity in specific neural tissues. GRIA4 (encoding GluA4) is preferentially expressed in the thalamus, where fast-cycling AMPA receptors enable the relay and filtering of sensory and motor signals. Elevated or dysregulated GluA4 expression in thalamic circuits could lower the threshold for glutamate-driven arousal at night, when the thalamus is supposed to enter a gating mode that blocks sensory input from reaching the cortex.

The direct evidence for thalamic glutamate excess in RLS comes from MR spectroscopy studies showing that thalamic Glx/creatinine ratios are significantly elevated in RLS patients compared to age-matched controls (1.20 ± 0.73 vs 0.80 ± 0.39, p=0.016), and — critically — this elevation correlates strongly with nocturnal wakefulness (r=0.61, p=0.007) but not with periodic leg movements²² MR spectroscopy studies showing that thalamic Glx/creatinine ratios are significantly elevated in RLS patients compared to age-matched controls (1.20 ± 0.73 vs 0.80 ± 0.39, p=0.016), and — critically — this elevation correlates strongly with nocturnal wakefulness (r=0.61, p=0.007) but not with periodic leg movements. This dissociation between glutamate and dopamine signatures (dopamine tracks the leg movements; glutamate tracks the arousal and sensory distress) suggests two semi-independent pathways, both of which contribute to the clinical syndrome.

Upstream of this glutamate excess, brain iron deficiency is the principal trigger³³ brain iron deficiency is the principal trigger. Iron is a cofactor for tyrosine hydroxylase (dopamine synthesis) and for adenosine synthesis; when brain iron drops, dopaminergic tone falls and the adenosine-mediated inhibitory brake on glutamate release weakens in parallel. Carriers of the rs10895816 A allele may have subtly elevated or altered GRIA4 expression at baseline, making the thalamic glutamate system more responsive to these iron-driven perturbations.

The Evidence

The 2024 RLS GWAS meta-analysis by Schormair, Zhao, Bell and colleagues⁴⁴ The 2024 RLS GWAS meta-analysis by Schormair, Zhao, Bell and colleagues
Published in Nature Genetics; the largest RLS genetic study ever conducted pooled 116,647 individuals with RLS and 1,546,466 controls of European ancestry, identifying 164 genome-wide significant risk loci — an eightfold expansion of the known RLS genetic architecture. Among these, rs10895816 at GRIA4 reached p=5×10⁻²⁵, far beyond the standard genome-wide significance threshold of 5×10⁻⁸ and well into the range that would survive any plausible multiple testing correction. The paper explicitly named GRIA4 (glutamate receptor 4) as one of the key "druggable" targets emerging from the data — a designation that means the encoded protein has established or potential pharmacological intervention points.

The identification of both rs10038916 (GRIA1) and rs10895816 (GRIA4) as independent genome-wide significant RLS loci in the same study is particularly meaningful. GRIA1 and GRIA4 encode two of the four GluA subunit types that co-assemble to form functional AMPA receptor tetramers. Finding GWAS signals in two subunit genes of the same receptor complex argues strongly that AMPA receptor biology — not merely a statistical coincidence — is a genuine functional pathway for RLS. This is consistent with the hypothesis that specific combinations of subunit compositions alter thalamic excitatory tone in ways that produce the sensory hyperarousal characteristic of RLS⁵⁵ specific combinations of subunit compositions alter thalamic excitatory tone in ways that produce the sensory hyperarousal characteristic of RLS.

The therapeutic implication is already partially exploited without knowing it: gabapentin and pregabalin, which have become preferred non-dopaminergic RLS treatments, reduce presynaptic glutamate and neurotransmitter release through α2δ calcium channel subunits. Their benefit in RLS may partly reflect suppression of the same GRIA4-mediated excitatory pathway this variant tags.

Rare coding mutations in GRIA4 cause a severe neurodevelopmental disorder called NEDSGA⁶⁶ neurodevelopmental disorder called NEDSGA
Neurodevelopmental disorder with or without seizures and gait abnormalities, OMIM 617864 — intellectual disability, seizures, and movement abnormalities from de novo heterozygous loss-of-function or gain-of-function variants. While rs10895816 is a common intronic variant with a far smaller effect size than these rare coding mutations, the existence of severe neurological phenotypes from GRIA4 disruption confirms the gene's dose-sensitive role in brain function and lends biological plausibility to subtler regulatory effects from the common variant.

Practical Implications

For carriers of the rs10895816 A allele, the actionable levers are the same ones that modulate the glutamatergic thalamic circuit more broadly. Brain iron optimization is primary — ferritin below 75 ng/mL correlates with RLS onset and severity, and restoring iron directly attenuates the hyperglutamatergic state by recovering dopaminergic and adenosinergic inhibitory tone. Medications that block dopamine receptors (certain antipsychotics, antiemetics, and antidepressants) are especially hazardous in this context because they further remove the inhibitory influence on thalamic glutamate. And if pharmacotherapy for RLS is needed, the genetic architecture points toward non-dopaminergic agents that address the glutamate excess rather than exclusively targeting the dopamine side.

RLS affects roughly 5–10% of adults of European descent; its prevalence is substantially lower in East Asian populations, a pattern that aligns with the much lower A allele frequency in East Asians (~69% vs ~43% in Europeans — note the A allele is actually more common in East Asians, but in that population, the G allele is rarer, which may relate to different genetic backgrounds for RLS risk overall).

Interactions

The most direct interaction is with rs10038916 at GRIA1, the other AMPA receptor subunit gene genome-wide significant for RLS in the same Schormair 2024 meta-analysis. GRIA1 (GluA1) and GRIA4 (GluA4) are both expressed in thalamic and cortical neurons and co-assemble into heteromeric AMPA receptor complexes. Carriers of risk alleles at both loci plausibly carry a compounded glutamatergic liability, though combined effect estimates have not been published separately. The pathway also intersects with brain iron homeostasis genes (BTBD9, which has the highest LD score for RLS and influences brain iron storage) and the MEIS1 locus, the earliest-discovered and highest-effect RLS GWAS hit.